Polycystic kidney is a congenital genetic disease. Patients with polycystic kidney often have a combination of renal failure and even progress to uremia, so the prognosis is relatively poor. About the new drugs for polycystic kidney treatment: First, the most common drug is vasopressin V2 receptor antagonist, which is commonly used clinically as tolvaptan. Tolvaptan has been confirmed by a large sample of randomized controlled studies to delay the increase of kidney volume and decrease of glomerular filtration rate, and has been approved for clinical use in Japan, Canada, EU, Korea and Switzerland, and the efficacy is relatively certain. For the indications of tolvaptan, it is generally recommended for adult autosomal dominant polycystic kidney patients under 50 years of age, and patients with glomerular filtration rate greater than 45 ml/min can be used. Second, commonly used drugs are growth inhibitor analogues, but growth inhibitor analogues are studied in fewer patients, the follow-up time is relatively short, and the efficacy is not very certain. Third, statins, such as pravastatin, have been studied in a randomized controlled study in children with polycystic kidney disease and have been shown to slow down the increase in kidney size and loss of kidney function.